By Dawn Kopecki, Jarrett Renshaw, Sabrina Valle and Ernest Scheyder

NEW YORK, October 2 (Reuters) -Eli Lilly was asked to produce more insulin; Pfizer to produce more of its top-selling cancer drug Ibrance and its cholesterol drug Lipitor; and London-based AstraZeneca to consider a new headquarters in the U.S., according to two sources.

Pharmaceutical executives are getting near-daily calls from staff at the White House – including Chief of Staff Susie Wiles – and senior figures at agencies like Health & Human Services and the Commerce Department, two sources familiar with the matter said.

But pharmaceutical companies are the tip of the iceberg.

The Trump administration is pursuing deals across up to 30 industries, involving dozens of companies deemed critical to national or economic s

See Full Page